Company profile
Regenerative Medicine | Vascversa
Vascversa is a Regenerative Medicine Company developing exciting new cell therapies that promote vascular regeneration and repair. Spun out of Queen's University Belfast and built on over 20 years of research.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
VascVersa develops a stem cell retrieval method, allowing high potency cells to be obtained from small samples of umbilical cord blood, for use in regenerative medical research.
The company is currently an embryonic spin-out arising from the research of Dr Reinhold Medina. The initial customer discovery was funded through the Innovate UK ICURe programme and carried out by ECR Dr Christina O'Neill. As of March 19 the company is in a fund-raising and planning phase.
The company is in early stages but we have managed to secure Innovate UK funding and private investment. The company has spun-out from QUB as a direct result of success in iCURE allowing a motivated post-doc to drive the company forward from the foundation of a successful academic research programme.
£42,500 was raised for the customer discovery and company set-up process from Innovate UK -ICURe programme. The company was invited to apply for £210K of non-dilutive Innovate UK funding (decision pending March 19)
1 Jun 2025 to 31 May 2026
**Public Description** **A regenerative medicine for vascular disease** VascVersa is developing a groundbreaking cell therapy known as Angicyte, designed to treat vascular ischaemic diseases, which are conditions caused by insufficient blood supply to tissues. Angicyte works by stimulating the formation of new blood vessels in areas with low oxygen levels...
1 Aug 2024 to 31 Jan 2026
VascVersa is developing an innovative cell therapy designed to revolutionize the treatment of chronic non-healing wounds, specifically focusing on diabetic foot ulcers (DFU). Despite extensive medical research, current available treatments fall short, with a staggering 39% of treated wounds failing to heal, primarily due to insufficient blood supply. This...
1 Jun 2024 to 31 Jan 2025
VascVersa is developing a radical new cell therapy called Angicyte for the treatment of ischaemic diseases (diseases characterised by lack of blood supply). Angicyte promotes the formation of new blood vessels and induces vascular healing, therefore will be of benefit for multiple vascular diseases. Research by the company and Queen's University Belfast h...
1 May 2022 to 30 Apr 2024
VascVersa is developing a revolutionary new cell therapy for the treatment of chronic non-healing wounds, in particular diabetic foot ulcers (DFU) and leg ulcers. Despite immense medical research, current available treatments are inadequate and 39% of treated wounds still fail to heal, largely due to a lack of blood supply. Diabetic ulcers remain an enorm...
1 Apr 2021 to 31 Mar 2022
1 Feb 2020 to 31 Dec 2021
"VascVersa (Versatile Vascular Stem Cells for Regenerative Medicine) Cardiovascular diseases are the top cause of death worldwide. There is an urgent need to find new treatments to repair damaged blood vessels as current approaches are not optimal. At VascVersa, we are committed to develop innovative regenerative medicine, and we have optimised a consiste...
